neratinib
PUMA-NER-4201
Phase 2 small_molecule completed
Quick answer
neratinib for HER2-mutant Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PUMA BIOTECHNOLOGY, INC.
- Indication
- HER2-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed